亞太藥業(002370.SZ):控股股東及其一致行動人被司法拍賣的2950萬股完成過户
格隆匯6月16日丨亞太藥業(002370.SZ)公佈,公司控股股東浙江亞太集團有限公司(“亞太集團”)持有的亞太藥業1100萬股股票、紹興柯橋亞太房地產有限公司(“亞太房地產”)持有的亞太藥業1600萬股股票於2021年04月20日被競拍成功;亞太房地產持有的亞太藥業100萬股、150萬股股票於2021年6月1日被競拍成功。近日,上述股份已在中國證券登記結算有限責任公司深圳分公司完成了相關過户登記手續。
此次股份拍賣完成後,控股股東亞太集團及其子公司亞太房地產、實際控制人陳堯根及其配偶鍾婉珍持股變動情況如下:


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.